Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (July 2023)
31 slides from Adalta's investor presentation, Jul 13, 2023
Slide 1: Next generation protein and cell therapies: solutions to debilitating diseases
For personal use only Next generation protein and cell therapies: solutions to debilitating diseases Tim Oldham PhD, CEO and Managing Director, AdAlta (ASX:1AD) Overview for investors, 13 July 2023
Slide 2: Disclaimer
Investor presentation – July 2023 2 Disclaimer For personal use only Investment in AdAlta is subject to This presentation may contain forward- There is no guarantee that the investment risk, including possible loss looking statements regarding the Company’s research and development of income and cap
Slide 3: AdAlta business and focus
Investor presentation – July 2023 3 AdAlta business and focus For personal use only Purpose: going where antibodies cannot to address debilitating diseases Producing a high-value, next generation protein and cell therapy product pipeline for diseases where traditional antibodies are ineffective Disc
Slide 4: AdAlta's portfolio: high value therapeutics and a platform to help other companies
Investor presentation – July 2023 4 AdAlta’s portfolio: high value therapeutics and a platform to help other companies address challenging diseases in fibrosis and immuno-oncology For personal use only Fibrosis: degenerative, progressive, fatal AdAlta’s AD-214 could meet a desperate need for new app
Slide 5: AD-214 program
For personal use only AD-214 program 5
Slide 6: The need: Idiopathic Pulmonary Fibrosis (IPF)
Investor presentation – July 2023 9 The need: Idiopathic Pulmonary Fibrosis (IPF) For personal use only Scarring of the lungs reduces lung function: irreversible, unpredictable, incurable >490,000 people living with IPF2 >40,000 people die every year 3.8 years median survival 88% aged 55 or older Tw
Slide 7: AdAlta's solution: AD-214 is being readied for Phase II clinical studies and partnering
Investor presentation – July 2023 7 AdAlta’s solution: AD-214 is being readied for Phase II clinical studies and partnering For personal use only AD-214: strong value proposition built so far Next steps to advance to Phase II First in class molecule targeting validated mode of Phase I extension stud
Slide 8: Potential for efficacy at clinically viable dosing regimen demonstrated
Investor presentation – July 2023 8 Potential for efficacy at clinically viable dosing regimen demonstrated For personal use only A. AD-214 has demonstrated efficacy in multiple animal models of fibrotic disease B. In humans, AD-214 was able to maintain more than 60% receptor occupancy (blocking) fo
Slide 9: Phase I extension study delivers new data in 2023 to support partnering and Phase II
Investor presentation – July 2023 9 Phase I extension study delivers new data in 2023 to support partnering and Phase II For personal use only AD-214 multidose Phase I extension clinical study • Evaluating safety, PK and PD of multiple 10 mg/kg doses Establishes safety of AD-214 at likely maximum do
Slide 10: The value: pharma companies license fibrosis assets for significant prices: IPF examples
Investor presentation – July 2023 10 The value: pharma companies license fibrosis assets for significant prices: IPF examples For personal use only Upfront payment Contingent Clinical Phase Date Licensor/target Licensee/acquirer Transaction to licensor milestones at transaction Aug-22 License US$80m
Slide 11: Co-developed immuno-oncology programs: i-CAR-cell therapies
For personal use only Co-developed immuno-oncology programs: i-CAR-cell therapies 11
Slide 12: The need: multifunctional CAR-cell therapies
Investor presentation – July 2023 12 The need: multifunctional CAR-cell therapies For personal use only Therapy involves re-engineering patient’s own immune cells so they “see” cancer as a pathogen – living drug, single dose, potentially curative >US$2.6 billion earned in 20223 US$20.3 billion CAR-T
Slide 13: AdAlta's solution: i-bodies enable superior CAR constructs (i-CARs)
Investor presentation – July 2023 13 AdAlta’s solution: i-bodies enable superior CAR constructs (i-CARs) For personal use only when combined with partner platforms Tiny i-bodies take up LESS room in inserted gene, enabling TWICE the engineered i-body targeting Tumor cell domain functionality Tumor C
Slide 14: i-CAR-T assets: Carina co-development collaboration status
Investor presentation – July 2023 14 i-CAR-T assets: Carina co-development collaboration status For personal use only AdAlta and Carina are combining i-bodies and a world class CAR-T platform to create i-CAR-Ts that could offer improved precision, performance and persistence i-body enabled CAR-T (i-
Slide 15: i-CAR-T: Valuable cell therapy partnering potential at pre-clinical proof of concept
Investor presentation – July 2023 15 i-CAR-T: Valuable cell therapy partnering potential at pre-clinical proof of concept For personal use only AdAlta i-bodies + Carina cell therapy platform = i-CAR-Ts for solid tumor patients 3 of 5 programs underway; 1 entering proof of concept Significant industr
Slide 16: Co-developed immuno-oncology programs: i-PET imaging
For personal use only Co-developed immuno-oncology programs: i-PET imaging 16
Slide 17: The need: Immuno-oncology (I/O) imaging
Investor presentation – July 2023 17 The need: Immuno-oncology (I/O) imaging For personal use only Immuno-oncology (I/O) drug market is worth US$95 billion1 … … but only 20-40% of patients respond2 to therapy Granzyme B (GZMB) is produced by immune cells to kill cancer: potential biomarker of I/O dr
Slide 18: AdAlta's solution: funded discovery, shorter timeline to royalties for GZMB i-PET imaging asset
Investor presentation – July 2023 18 AdAlta’s solution: funded discovery, shorter timeline to royalties for GZMB i-PET imaging asset For personal use only AdAlta i-bodies + GE PET technology = GZMB i-PET asset to evaluate the effectiveness of immuno-oncology drugs ü Fully funded discovery program pl
Slide 19: The investment opportunity
For personal use only The investment opportunity 19
Slide 20: i-bodies are a powerful drug discovery tool to engage intractable targets
Investor presentation – July 2023 20 i-bodies are a powerful drug discovery tool to engage targets that are intractable for traditional antibodies For personal use only Small Antibodies i-bodies™ Flexible, modular formats Molecules Current pipeline focus CAR cell therapy ADC/ radiotherapeutic Bi-spe
Slide 21: AdAlta's pipeline so far: five active assets plus additional partnering opportunities
Investor presentation – July 2023 21 AdAlta’s pipeline so far: five active assets plus additional partnering opportunities For personal use only Discovery Non-clinical Clinical Indication Target Product Partner (route) Lead IND Discovery Preclinical Phase I Phase II optimisation enabling IV Availabl
Slide 22: Three partnering initiatives to generate return on investment
Investor presentation – July 2023 22 Three partnering initiatives to generate return on investment For personal use only AD-214 partnering prospects by stage1 Slate of partnering initiatives 1. Out-licence AD-214 N America Europe N Asia 3 1 1 3 2 2 1 4 2. Out-license i-body discovery 4 platform 3. A
Slide 23: Upcoming CY2023 milestones: AD-214 and i-CAR-T data
Investor presentation – July 2023 23 Upcoming CY2023 milestones: AD-214 and i-CAR-T data + multiple transaction upside potential For personal use only Strategy Milestone Impact • HREC approval, 1st participant Phase I extension (Q3 23) Realise Generates new data for partnering, shortens Phase II stu
Slide 24: Corporate snapshot
Investor presentation – July 2023 24 Corporate snapshot For personal use only Key financial details (12 July 2023) Share price performance (ASX:1AD) (last 12 months) 0.07 6.0 HQ and operations Melbourne, Australia Market capitalisation A$13.2m 0.06 5.0 Share price (12 month closing range) A$0.03 ($0
Slide 25: Experienced, in-house team to execute from discovery through product development
Investor presentation – July 2023 25 Experienced, in-house team to execute from discovery through product development BOARD EXECUTIVE SCIENTIFIC ADVISORY BOARD For personal use only Paul MacLeman Patrick James, PhD Mick Foley, PhD CHAIR DIRECTOR, PLATFORM FOUNDING CHIEF AND PRODUCT SCIENTIST DISCOVE
Slide 26: Investment proposition
Investor presentation – July 2023 26 Investment proposition For personal use only Fibrosis/inflammation Immuno-oncology i-body platform to create value AD-214: Phase II and partnering in $4.3b 2 co-development collaborations market1 (4 programs) in $20b2 and $6b3 markets Strategy: invest to maintain
Slide 27: Contact
For personal use only Contact: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au
Slide 28: AD-214: efficacy validated in IPF mouse model; safety and target engagement in Phase I
Investor presentation – July 2023 28 AD-214: efficacy validated in IPF mouse model; safety and target engagement in Phase I For personal use only AD-214 inhibited development of lung fibrosis in a mouse AD-214 was well tolerated in Phase I clinical trials and model at a wide range of doses and dose
Slide 29: Clinically feasible, two weekly IV dosing regimens support sufficient receptor occupancy
Investor presentation – July 2023 29 Clinically feasible, two weekly IV dosing regimens support sufficient receptor occupancy for to inhibit fibrotic processes 1. Ex vivo cell migration is a model fibrotic process and inhibition of migration is a model of efficacy For personal use only • Maximum eff
Slide 30: i-body-like sdAb CAR-T therapies are an emerging, validated approach
Investor presentation – July 2023 30 i-body-like sdAb CAR-T therapies are an emerging, validated approach For personal use only GROUP YEAR STAGE SDAB CAR TARGET AVAILABLE RESULTS Proof of principle AdAlta Ltd/Carina Biotech 2022 Undisclosed (in vitro) P3 results for n=97 patients Johnson and Johnson
Slide 31: Building the first iCAR-T cell therapy: proof of principle results
Investor presentation – July 2023 31 Building the first iCAR-T cell therapy: proof of principle results For personal use only i-body enabled CAR-T (iCAR-T) cells have been successfully generated by Carina and demonstrate in vitro cell killing (lysis)1 Experimental details • LOVO and LIM1215 are colo